Clinical Trial Detail

NCT ID NCT03997123
Title Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CapItello290)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

triple-receptor negative breast cancer

Therapies

Paclitaxel

Capivasertib + Paclitaxel

Age Groups: adult senior

No variant requirements are available.